linjc16/ctgov huggingface dataset:
The Effect of the Combination of Cleanser and Moisturizer Product K

Study Overview
=================
Brief Summary
-----------------
This study is conducted to evaluate the effectiveness of product K cleanser and moisturizer when use in combination for skin rejuvenation. The study duration is 8 weeks and the skin assessment will be carried out at baseline, week 2, week 4 and week 8.The main questions this study aims to answer are: The effect of cleanser and moisturizer K when use in combination on skin hydration. The effect of cleanser and moisturizer K when use in combination on skin elasticity. To observe any adverse effect occurrence with the usage of the products.

Official Title
-----------------
The Effect of the Combination of Cleanser and Moisturizer Product K on Skin Rejuvenation

Conditions
-----------------
Cosmetic, Aesthetic, Healthy

Intervention / Treatment
-----------------
* Other: Product K cleanser and moisturizer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Malaysia citizen Male and female (age 20-60 years old) Exclusion Criteria: Participants taking isotretinoin Immunocompromised patients Participant who undergo any cosmetic procedures such as laser & light treatment for the past three months. Participant with a history of facial surgery.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Product K cleanser and moisturizer<br>Participants will used product K cleanser and moisturizer twice daily for 8 weeks | Other: Product K cleanser and moisturizer<br>* Product K cleanser and moisturizer contain ingredients that may improve skin hydration and elasticity<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in skin hydration from baseline and at week 2, week 4 and week 8 after using product K cleanser and moisturizer | Skin hydration will be assessed using JANUS III skin analyzer | Baseline, week 2, week 4 and week 8 | 
| Change in skin elasticity from baseline and at week 2, week 4 and week 8 after using product K cleanser and moisturizer | Skin elasticity will be assessed using JANUS III skin analyzer | Baseline, week 2, week 4 and week 8 | 
| Adverse effect after using product K cleanser and moisturizer | Based on adverse effect occurrence on participants that occur during study period (8 weeks) | Week 8 |
Outcome Factors of Pneumonia Patients in Critical Care Unit

Study Overview
=================
Brief Summary
-----------------
To determine the risk factor that affect pneumonic patients at the critical care unit regarding the history investigation and clinical data

Detailed Description
-----------------
Pneumonia remains a serious illness with important clinical impact . It is defined as acute respiratory tract infection that affect lower respiratory tract ,it is classified as community acquired pneumonia (CAP), hospital acquired pneumonia (HAP) and ventilator associated pneumonia . In this work we assess the factors that affect the prognosis of critically ill patients with pneumonia regarding the age ,sex ,smoking, other co morbidity as diabetes mellitus, hypertension , liver diseases , kidney diseases, heart diseases and chest diseases, clinical date and investigation .

Official Title
-----------------
Factors Predicting Outcome of Admitted Pneumonia Patients in Critical Care Unit

Conditions
-----------------
Pneumonia Aggravated

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1- Age above 18 yrs. 2- Critically ill patients admitted to ICU with clinical manifestations of pneumonia in assuit university hospital Exclusion Criteria: 1- Age below 18 yrs. 2- Patients don't have critical illness 3- Patient who refused to contribute in this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the risk factor that affect pneumonic patients at the critical cre unit and ICU . | to develop and determine the risk factor that affect critically ill patients with pneumonia and the mortality rate . | 1 year |
Chronic Anergic-anhedonic Depression Open Trial

Study Overview
=================
Brief Summary
-----------------
A form of depression called 'dopamine-sensitive anergic-anhedonic syndrome is usually resistant to standard therapies (TRAD). On the other hand, they respond to dopaminergic approaches for which recommendations have been developed: DATA ('Dopaminergic Antidepressant Therapy Algorithm'). These are two stages starting with non-selective monoamineoxidase inhibitors (MAOI) or dopamine D2 receptor agonists (D2RAG) in 'monotherapy' (DATA1) and proposing to combine them in the event of a partial response (DATA2). The effectiveness of this approach in the management of TRAD has not yet been evaluated in routine care. The aim of this study is to evaluate the feasibility and effectiveness in routine care of the DATA recommendations in the management of TRAD presenting to a specialized consultation for resistant depression (short and long-term results).

Official Title
-----------------
Chronic Anergic-anhedonic Depression Open Trial

Conditions
-----------------
Depressive Disorder, Treatment-Resistant

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major patient (≥18 years old) Man or woman Patient covered for consultation at the Expert Resistant Depression Center of Alsace (CEDRA) (CHU-Strasbourg branch) for TRAD between 01 January 2013 and 31 March 2023 Patient not opposing to the reuse of their data for the purposes of this research Exclusion Criteria: Patient having expressed opposition to participating in the study Patient under judicial protection Patient under guardianship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients in remission; Remission time; Survival curves for remissions and responses |  | 3 months after the patient was taken care of at the Strasbourg University Hospital | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depressive Disorder, Treatment-Resistant, Anergic-anhednic, TRD, TRAD, MAOI, dopamine D2 receptor agonists, D2RAG, dopamine-sensitive
IASLC Grading System as a Predictor for EGFR-TKI Therapy

Study Overview
=================
Brief Summary
-----------------
The investigators previously validated the grading system proposed by International Association for the Study of Lung Cancer (IASLC) for invasive nonmucinous lung adenocarcinoma (LADC) for its reproducibility, prognostication function and predictive value of adjuvant chemotherapy (ACT). In this exploratory study, the investigators aimed to investigate the role of IASLC grading system in EGFR tyrosine kinase inhibitor (TKI) therapy selection either as adjuvant or palliative therapy.

Official Title
-----------------
The IASLC Grading System as a Predictor for EGFR-TKI Therapy in EGFR-mutant Lung Adenocarcinoma

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: IASLC grading system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: invasive lung adenocarcinoma patients who underwent complete resection with positive EGFR mutations in exons 18-21. Exclusion Criteria: adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive mucinous adenocarcinoma and other variants of adenocarcinoma patients with pathologic slides unavailable for re-evaluation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: IASLC grading system|A cohort of 2160 patients with invasive nonmucinous EGFR-mutant LADCs were retrospectively collected and classified according to the IASLC grading system. The role of IASLC grading system in EGFR tyrosine kinase inhibitor (TKI) therapy selection either as adjuvant or palliative therapy was investigated.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease-free survival | DFS was defined as time from initiation of surgery to date of first event (recurrence or death) | 5 years | 
| Progression-free survival | PFS was defined as time from initiation of systemic palliative treatment to date of disease progression or death for 1L treatment of each patient and the initiation time was re-assigned additionally for each drug applied during the treatment history of the patients regardless of line of therapy (all lines) | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | was defined as time from surgery to date of death resulting from any cause in ADJUVANT subgroup and from 1L systemic palliative treatment assignment to date of death resulting from any cause in RECURRENCE subgroup. | 5 years |
Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to demonstrate non-inferiority of Restylane Lyft with Lidocaine versus a comparator-control for augmentation of the chin region to improve the chin profile.

Official Title
-----------------
A Randomized, Evaluator-blinded, Parallel Group, Comparator-controlled, Multicenter Study to Evaluate the Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile

Conditions
-----------------
Chin Augmentation, Chin Retrusion

Intervention / Treatment
-----------------
* Device: New Dermal Filler
* Device: FDA appoved Dermal Filler


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or non-pregnant, non-breastfeeding females, 22 years of age or older Intent to receive treatment for augmentation and correction of retrusion in the chin region. Exclusion Criteria: Known/previous allergy of hypersensitivity to any injectable hyaluronic acid (HA) gel or gram-positive bacterial proteins. Known/previous allergy or hypersensitivity to local anesthetics, e.g., lidocaine or other amide-type anesthetics. Previous or present multiple severe allergies or severe allergies, such as manifested by anaphylaxis or angioedema or family history of angioedema. Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from the subnasale. Any previous aesthetic procedures or implants Presence of any disease or lesion near or on the area to be treated.

Ages Eligible for Study
-----------------
Minimum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: New Dermal Filler for indication<br>hyaluronic acid dermal filler | Device: New Dermal Filler<br>* hyaluronic acid<br>|
| Active Comparator: Active Comparator: FDA approved Dermal Filler<br>hyaluronic acid dermal filler | Device: FDA appoved Dermal Filler<br>* hyaluronic acid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Effectiveness Objective | Change from Baseline in the Blinded Evaluators' live assessment using the GCRS (Galderma Chin Retrusion Scale). | 3 months after last treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary Effectiveness Objective | Responder rate based on the Blinded Evaluator's live assessment using the GCRS (Galderma Chin Retrusion Scale) at 6, 9, and 12 months after last treatment. | 6, 9, and 12 months after last treatment. |
A New Risk Score for Predicting 1-year Mortality in Older r Maintenance Hemodialysis Patients.

Study Overview
=================
Brief Summary
-----------------
The goal of this retrospective observational cohort study is to analysis the 1-year mortality in older patients undergoing maintenance hemodialysis. The main question it aims to answer is to explore the risk factors affecting the mortality of older patients undergoing maintenance hemodialysis and establish a risk prediction score. Data of older patients (age ≥65 years old) undergoing maintenance hemodialysis were collected from 2012-1-December 31, 2014, with data from Beijing Blood Purification Quality Control and Improvement Center (BJHDQCIC). Logistic regression model was used to evaluate the 1-year mortality and the influence of predictive factors. Internal validation of the model was performed using the bootstrap 1000 repeat sampling method. Area under receiver operating characteristic curve (AUC) was used to evaluate the predictive ability of the model.

Official Title
-----------------
A New Risk Score for Predicting 1-year Mortality in Older r Maintenance Hemodialysis Patients.A Cohort Study in Beijing.

Conditions
-----------------
Maintenance Hemodialysis, Older Patient

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥65 years. More than 6-month history of hemodialysis,the frequency is 3 times a week, and the dialysis time is 4 hours each. The dialysate Ca concentration was 1.5 mmol/L and the bicarbonate level was 32 -- 35 mmol/L. Exclusion Criteria: Lack of demographic information, clinical history, or relevant laboratory values (including pre-dialysis serum calcium, phosphorus, iPTH, haemoglobin, albumin, creatinine, total cholesterol, and Kt/v for urea).

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the 1-year mortality in older patients undergoing maintenance hemodialysis |  | Data of older patients (age ≥65 years old) undergoing maintenance hemodialysis were collected from 2012-1-December 31, 2014, with data from Beijing Blood Purification Quality Control and Improvement Center (BJHDQCIC). | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Older patients, maintenance hemodialysis, mortality, risk prediction score.
The Effectiveness of a Health Education Intervention to Reduce Anxiety in Quarantined COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
we aimed to assess the impact of health education on the anxiety level of COVID-19 patients during the isolation period.

Detailed Description
-----------------
This is a randomized controlled trial conducted between February 2021 and June 2021. Patients tested positive for Covid-19 with mild to moderate forms were randomized to Education (n=267) or control (n=269). The education group received a phone health education session on day 1 (D1) following the diagnosis. The three components of the health education intervention were an explanation of the coronavirus disease, what to do in the event of complications, and the recommended preventive measures. The two groups received a telephone evaluation of their Hospital Anxiety and Depression scores on (D1) and day seven D7 following the positive diagnosis. The primary outcome was the rate of anxiety reduction in each group at D7 based on a HAD-A score ≥ 8. Secondary outcomes were the rate of anxiety reduction at D7 based on a HAD-A score ≥ 11, the percentage of people complying with isolation and the scores of adherence to preventive measures during the isolation in each group.

Official Title
-----------------
The Effectiveness of a Health Education Intervention to Reduce Anxiety in Quarantined COVID-19 Patients: A Randomized Controlled Trial

Conditions
-----------------
Health Education, COVID-19, Quarantine, Anxiety, Pandemic

Intervention / Treatment
-----------------
* Other: health education intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with Covid-19 after positive PCR or positive antigen rapid test, over 18 years of age, who did not require hospitalization Exclusion Criteria: Patients not reachable at the first day phone call of the diagnosis and patients unable to answer the telephone questionnaire due to their cognitive state.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Education<br> | Other: health education intervention<br>* health education intervention<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The rate of anxiety reduction | The rate of anxiety reduction in each group at Day 7 based on a HAD-A score ≥ 8 | One week (7 days) after the COVID 19 diagnosis |
Virtual Specialty Clinic for Fibromyalgia Care

Study Overview
=================
Brief Summary
-----------------
This is an ongoing, prospective, and retrospective cohort study of fibromyalgia patients who receive clinical care at Swing Care (a fibromyalgia virtual specialty clinic). Deidentified data on demographics, clinical outcomes, patients' treatment engagement and preference, as well as patients' satisfaction are obtained and analyzed via retrospective and prospective chart review. A waiver of informed consent has been approved by the reviewing Institutional Review Board.

Official Title
-----------------
Virtual Specialty Clinic for Fibromyalgia Care

Conditions
-----------------
Fibromyalgia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients of Swing Care between 1 Oct, 2022 and 1 Oct, 2027, who received clinical evaluations and/or treatments according to Swing Care's standard clinical care protocol. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographic and clinical data obtained via chart review [ Time Frame: 5 years ] | This is a clinic based registry of fibromyalgia patient outcomes from patients at the Swing Care clinic to be collected over time. | 01 Oct 2022 - 01 Oct 2027 |
An Observational Study of Patients With Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
TARGET-KIDNEY is an observational research study to conduct a comprehensive review of outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESKD).

Official Title
-----------------
An Observational Study of Patients With Chronic Kidney Disease

Conditions
-----------------
Kidney Disease, Chronic, End Stage Kidney Disease

Intervention / Treatment
-----------------
* Other: Observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Disease Cohort Inclusion Criteria: Adult* patients at the time of enrollment with a diagnosis of CKD/ESKD by ICD-10 code in the EHR interface Exclusion Criteria: Death Manual removal (sponsor or site request) No EHR interface encounter > 3 years Engaged Cohort Inclusion Criteria: Adult * patients diagnosed and managed for CKD/ESKD invited to participate Ability to provide written informed consent Exclusion Criteria: Patient expressed desire to withdraw consent to complete PROs Failure to complete PROs within 24 weeks of initial invitation Greater than 24 months lapse of survey completion after baseline surveys completed Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Disease Cohort<br> | Other: Observational<br>* Observational<br>|
| Engaged Cohort<br> | Other: Observational<br>* Observational<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To characterize the natural history of disease in patients with CKD/ESKD. |  | 20 Years | 
| To assess safety and effectiveness of CKD/ESKD treatments and treatments for complications of either condition |  | 20 Years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate provider management practices in the treatment of patients with CKD/ESKD |  | 20 Years | 
| To evaluate longitudinal and patient reported outcomes in CKD/ESKD |  | 20 Years | 
| To select and evaluate quality of care measures for patients with CKD/ESKD |  | 20 Years |